1. Accueil >
  2. NeuroSearch upgrades its guidance for 2017 >
Nasdaq

NeuroSearch upgrades its guidance for 2017

17-11-2017

Company announcement
17 November 2017

NeuroSearch upgrades its guidance for 2017 from an operating loss of DKK 2.3-3.3 million, to an operation loss of approximately DKK 1 million. The outlook does not include any income from the possible divestment of additional Company assets or potential income from the Company’s agreement with Teva.

Contact
Allan Andersen, CEO, mobile +45 4016 3864.

About NeuroSearch
NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.